6 Psychiatry Headlines You Missed in March 2026

March 2026 featured a range of developments across psychiatry, including emerging psychedelic therapies, accelerated neuromodulation strategies, ethical considerations around artificial intelligence in mental health care, and new observational data linking metabolic therapies to psychiatric outcomes.

This month in review features the top 6 headlines in psychiatry.

Growing Use of AI in Psychiatry

Your Patient's New Therapist Is an AI. Now What?

Growing patient use of generative artificial intelligence tools for mental health support prompted discussion among psychiatrists and ethicists regarding safety, oversight, and clinical integration. Experts emphasized that patients are increasingly turning to conversational AI platforms for therapy-like interactions, raising concerns about accuracy, crisis management, and therapeutic boundaries. Clinicians highlighted the need for guidance on how to counsel patients using these tools, while acknowledging potential benefits such as increased accessibility and stigma reduction.

The discussion underscored that AI-based support may complement, but not replace, clinician-delivered psychotherapy, particularly for patients with complex psychiatric conditions or suicide risk.

Experts:

• 1 bioethicist: Dominic Sisti, PhD, from Penn Medicine
• 3 psychiatry experts: Richard Miller, MD (Elwyn Adult Behavioral Health), Hans Eriksson, MD, PhD (HMNC Brain Health), and Darlene King, MD (University of Texas Southwest Medical Center).

Latest Psychedelic Research in Depression

Single-Day GH001 for TRD Shows Rapid Response, With Michael E. Thase, PhD

A phase 2b trial of inhaled mebufotenin (GH001) demonstrated rapid and clinically meaningful improvement in treatment-resistant depression (TRD) following a single-day individualized dosing regimen. Participants received up to 3 escalating doses within 1 treatment session, with symptom improvements observed within 1 week.

In a randomized cohort, remission by day 8 occurred in 57.5% of treated patients compared with none receiving placebo, with a large effect size and rapid onset of benefit. Investigators highlighted the potential scalability of a single-day psychedelic-based intervention relative to multi-session treatment models.

Psychedelic Therapy Matches Efficacy of Antidepressants in MDD, With Balázs Szigeti, PhD

A meta-analysis evaluating psychedelic-assisted therapy versus antidepressants in major depressive disorder (MDD) found comparable symptom improvement when accounting for trial blinding differences. Investigators noted that psychedelic-assisted therapy produced robust antidepressant effects but did not demonstrate superiority over open-label antidepressant treatment.

The findings suggested psychedelic therapy may expand treatment options rather than replace established pharmacotherapy, with further research needed to assess functional outcomes and real-world implementation.

New Deep TMS Data

Accelerated Deep TMS Matches Standard Outcomes in TRD in 6 Days

Accelerated deep transcranial magnetic stimulation (dTMS) delivered over 6 days produced clinical outcomes comparable to standard multiweek treatment in MDD. A multisite noninferiority trial showed similar response and remission rates while shortening treatment duration.

Accelerated protocols also demonstrated faster symptom improvement and reduced time to remission, supporting their potential to improve access and adherence among patients with treatment-resistant depression.

Accelerated rTMS Matches Conventional Protocol in TRD, With Andrew Leuchter, MD

Separate data comparing accelerated repetitive TMS (rTMS) to conventional once-daily treatment found both approaches produced significant reductions in depressive symptoms, with no statistically significant difference in efficacy.

Investigators noted that compressing treatment into a single week may improve adherence and reduce disruption to daily functioning, offering practical advantages for patients and clinics.

Semaglutide Not Linked to Suicide

Semaglutide Linked to Lower Suicidality Risk in Diabetes, With Mark Taylor, MD

Real-world registry data suggested glucagon-like peptide-1 receptor agonists, including semaglutide, were associated with reduced suicidality, anxiety, and psychiatric-related sick leave among patients with type 2 diabetes. Investigators used a within-individual design comparing treatment and non-treatment periods for the same patients, strengthening causal inference.

The findings counter earlier safety concerns and highlight potential mental health benefits of metabolic therapies, although experts emphasized these agents should not be considered primary psychiatric treatments.